

ABSTRACT

This invention relates to novel crystalline polymorphic forms of zaleplon (N-[3-(3-cyanopyrazolo[1,5a]pyrimidin-7-yl)phenyl]-N-ethylacetamide), methods for the preparation thereof, and their use as anxiolytic, antiepileptic, and sedative-hypnotic agents and skeletal muscle relaxants.